CD8A and neoplasm: Such therapy is highly dependent on specific T-cell receptors (TCR)—transduced T-cells, usually CD8+ effector memory T cells, and the presentation of neoepitopes by tumor-specific Human Leukocyte Antigen (HLA) molecules on the cell surface of tumor cells [77].